Insider Trading Alert - BIIB, VRX And AME Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 5, 2014, 233 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.59 to $85,937,500.00.

Highlighted Stocks Traded by Insiders:

Biogen Idec (BIIB) - FREE Research Report

Sandrock Alfred who is Grp SVP, Chief Medical Officer at Biogen Idec sold 3,171 shares at $342.58 on March 5, 2014. Following this transaction, the Grp SVP, Chief Medical Officer owned 15,407 shares meaning that the stake was reduced by 17.07% with the 3,171-share transaction.

The shares most recently traded at $346.15, up $3.57, or 1.03% since the insider transaction. Historical insider transactions for Biogen Idec go as follows:

  • 4-Week # shares sold: 9,753
  • 12-Week # shares sold: 28,428
  • 24-Week # shares sold: 34,785

The average volume for Biogen Idec has been 1.4 million shares per day over the past 30 days. Biogen Idec has a market cap of $81.1 billion and is part of the health care sector and drugs industry. Shares are up 22.74% year-to-date as of the close of trading on Wednesday.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. The company has a P/E ratio of 43.9. Currently there are 14 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIIB - FREE

TheStreet Quant Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Idec Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Valeant Pharmaceuticals International (VRX) - FREE Research Report

Provencio Norma Ann who is Director at Valeant Pharmaceuticals International sold 5,000 shares at $141.62 on March 5, 2014. Following this transaction, the Director owned 142,206 shares meaning that the stake was reduced by 3.4% with the 5,000-share transaction.

The shares most recently traded at $138.57, down $3.05, or 2.2% since the insider transaction. Historical insider transactions for Valeant Pharmaceuticals International go as follows:

  • 4-Week # shares bought: 2,536
  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 186,783
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 191,783
  • 24-Week # shares sold: 15,000

The average volume for Valeant Pharmaceuticals International has been 1.5 million shares per day over the past 30 days. Valeant Pharmaceuticals International has a market cap of $49.0 billion and is part of the health care sector and drugs industry. Shares are up 24.56% year-to-date as of the close of trading on Wednesday.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. The stock currently has a dividend yield of 0.95%. Currently there are 10 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRX - FREE

TheStreet Quant Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full Valeant Pharmaceuticals International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Ametek (AME) - FREE Research Report

Jones Timothy N who is President - Electromechanical at Ametek sold 20,000 shares at $53.60 on March 5, 2014. Following this transaction, the President - Electromechanical owned 54,444 shares meaning that the stake was reduced by 26.87% with the 20,000-share transaction.

The shares most recently traded at $53.70, up $0.10, or 0.19% since the insider transaction. Historical insider transactions for Ametek go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 1,000
  • 24-Week # shares sold: 15,000

The average volume for Ametek has been 925,100 shares per day over the past 30 days. Ametek has a market cap of $13.2 billion and is part of the industrial goods sector and industrial industry. Shares are up 2.01% year-to-date as of the close of trading on Wednesday.

AMETEK, Inc. manufactures and sells electronic instruments and electromechanical devices in North America, Europe, Asia, and South America. The company operates in two segments, Electronic Instruments Group and Electromechanical Group. The stock currently has a dividend yield of 0.45%. The company has a P/E ratio of 25.6. Currently there are 5 analysts that rate Ametek a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AME - FREE

TheStreet Quant Ratings rates Ametek as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Ametek Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%